Compare RAPP & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAPP | NVCR |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2024 | 2015 |
| Metric | RAPP | NVCR |
|---|---|---|
| Price | $29.89 | $12.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $47.80 | $28.42 |
| AVG Volume (30 Days) | 368.1K | ★ 1.8M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $642,269,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $6.43 | $10.70 |
| 52 Week High | $42.27 | $34.13 |
| Indicator | RAPP | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 56.12 |
| Support Level | $28.03 | $10.79 |
| Resistance Level | $31.00 | $13.94 |
| Average True Range (ATR) | 1.83 | 0.61 |
| MACD | 0.11 | 0.20 |
| Stochastic Oscillator | 72.79 | 69.68 |
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.